2008 Conference Presentations

15th Annual International Symposium on HCV and Related Viruses. October 2008, San Antonio Texas. Identification of a novel receptor for HCV entry. Dr. Flossie Wong-Staal, speaker.

US-Korea Conference on Science, Technology, and Entrepreneurship (UKC). August 2008. San Diego, California. Drug Discovery: Screening of Hepatitis C Virus (HCV) Entry Inhibitors. Dr. Haekyung Lee, Invited speaker.

BIT First Annual World Summit of Antivirals. July 2008. Kunming China. Novel inhibitors and receptor for HCV infection. Dr. Flossie Wong-Staal, Keynote speaker.

CHI Drug Discovery Chemistry 2008. HCV Drug Discovery. April 2008. La Jolla, CA. Developing First in Class Drugs Targeting HCV Entry. Dr. Flossie Wong-Staal, Invited Speaker.

Upcoming 2008 Conference Presentations

BIT First Annual World Summit of Antivirals. July 2008. Kunming China. Viral Villains: from AIDS to Hepatitis. Dr. Flossie Wong-Staal, Keynote speaker.

2008 ASCO Annual Meeting, Chicago, IL, June 2008. OncoMetTM targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by novel combination strategies. Dr. Henry QX Li, presentation.

2008 AACR Annual Meeting, San Diego, CA, April 2008. Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by novel combination strategies. Dr. Dehua (Derek) Yu, presentation.

CHI Drug Discovery Chemistry 2008. HCV Drug Discovery. April 2008. La Jolla, CA. Developing First in Class Drugs Targeting HCV Entry. Dr. Flossie Wong-Staal, Invited Speaker.

2007 Conference Presentations

Cambridge Healthtech Institute’s Fourth Annual Meeting on Advances in Cancer Immunotherapeutics. Cambridge, MA, August 21-24, 2007. Personalized cancer vaccine via oncolytic viratherapy. Dr. Henry QX Li, Speaker.

IBC's 3rd International Conference on Ocular Anti-angiogenesis. Cambridge, MA, April 16-17, 2007. IMS2186: Intraocular properties of a novel long acting anti-proliferative and anti-angiogenic agent for wetAMD. Dr. Henry QX Li, presentation.

GTCbio’s Apoptosis in Drug Discovery. March 22-23, 2007 in San Diego, CA. Discover Novel Anti-cancer Stragies via Intervention to the Transformation Relevant Apoptosis Pathway. Dr. Henry QX Li, Speaker.

Pacific Forum on Life Science Alliances 2006 (Panel discussion: Outsourcing Trend Across the Pacific) Dr. Henry QX Li, Speaker.

IBC's 3rd International Conference on Ocular Anti-angiogenesis. Cambridge, MA, March 29, 2006. Evaluate IMST9s as a potential sustained treatment for wet AMD. Dr. Henry QX Li, presentation.

Advances in Functional Genomics. San Francisco CA, April 25-16, 2006. A novel nuclear receptor family-specific RNAi library based on partially randomized consensus sequences for identifying the receptors involved in A beta degradation. Dr.Henry QX Li, speaker.

2005 Conference Presentations

2005 International Meeting on Human Viruses and AIDS. Baltimore, MD, August 30-September 2, 2005. A New Inducible RNAi Model for Cancer Target Validation in vivo. Dr. Flossie Wong-Staal, Speaker.

The 3rd Annual Congress of International Drug Discovery Science and Technology. Shanghai, China, October 28-31, 2005. Dr. Flossie Wong-Staal, Speaker.

IBC, International Conference, Early Efficacy Assessment. Boston, MA, June 6-8, 2005. A new regulated RNAi-based xenograft model for in vivo efficacy evaluation of cancer targets. Dr. Henry QX Li, Speaker.

San Diego Bio-Pharma Conference 2005, UCSD Price Center, June 4, 2005. A new regulated RNAi-based xenograft model for in vivo efficacy evaluation of cancer targets. Dr. Henry QX Li, Speaker.

Strategic Research Institute (SRI). January 24-25, 2005. Preclinical Development. A new xenograft model for in vivo efficacy evaluation of cancer targets. Dr. Henry Q.X. Li, Speaker

Emerging Technologies in Drug Discovery (EmTech2005), South San Francisco, April, 2005. A new xenograft model for in vivo efficacy evaluation of cancer targets. Dr. Henry QX Li, Speaker

AACR the Molecular Targets and Cancer Therapeutics Meeting. Philadelphia, PA, October 2005. Dr. Henry QX Li, Presentation.

IBC Antibody Engineering 2005. San Diego, CA, December 5-8, 2005. HE60, an orphan receptor, is a potential antibody therapeutic target for cancer. Dr. Henry QX Li, Presentation.

IBC Antibody Engineering 2005. San Diego, CA, December 5-8, 2005. Orphan receptor HE26 plays role in cell transformation and tumorigenesis involving cell adhesion pathway. Dr. Ning Ke, Presentation.

IBC Antibody Engineering 2005. San Diego, CA, December 5-8, 2005. Expression and characterization of a GPCR protein, a potential antibody therapeutic target, in mammalian cells. Dr. Hongwen Ma, Presentation.

CHI-RNAi, San Francisco, CA, May 2005. Functional analysis of a novel oncology target using RNAi and genome-wide Expression profiling. Presentation by Dr. Terif Awad (Affymetrix).

AACR Annual Meeting 2005, Anaheim, CA, April 2005. A new inducible RNAi based xenograft model to assess tumor response to the silencing of cancer target. Dr. Henry QX Li, Presentation.

AACR Annual Meeting 2005, Anaheim, CA, April 2005. Novel cancer drug targets: Validation and mechanistic studies. Dr. Ning Ke, Presentation.

AACR Annual Meeting 2005, Anaheim, CA, April 2005. PHTS, a novel putative tumor suppressor is involved in the transformation reversion of HeLa cells independent of the p53 pathway. Presentation, Dr. Dehua (Derek) Yu

2005 Keystone Antibody therapeutic, February 2005. Complement Factor I Is Highly Over-expressed In Gliomas Relative To Normal Brain Tissue And Is A Potential New Target For Radioimmunotherapy of Primary Brain Tumors. Dr. Nicholas Paoni, Presentation.